Enlivex Therapeutics (NASDAQ:ENLV) Shares Up 16.5% – Still a Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock price traded up 16.5% during mid-day trading on Friday . The stock traded as high as $1.24 and last traded at $1.20. 431,934 shares changed hands during trading, an increase of 493% from the average session volume of 72,780 shares. The stock had previously closed at $1.03.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a report on Friday, February 7th.

Enlivex Therapeutics Trading Up 16.5 %

The stock has a market capitalization of $25.69 million, a price-to-earnings ratio of -1.22 and a beta of 0.99. The company’s 50 day moving average is $1.13 and its 200 day moving average is $1.26.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Analysts anticipate that Enlivex Therapeutics Ltd. will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Enlivex Therapeutics

Large investors have recently modified their holdings of the company. Two Sigma Securities LLC purchased a new stake in Enlivex Therapeutics in the 4th quarter valued at $26,000. Renaissance Technologies LLC increased its stake in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after purchasing an additional 84,203 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at about $742,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.